Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glaucoma | 37 | 2024 | 1182 | 6.590 |
Why?
|
Optic Disk | 16 | 2024 | 421 | 5.590 |
Why?
|
Glaucoma, Open-Angle | 21 | 2023 | 734 | 5.020 |
Why?
|
Corneal Diseases | 13 | 2023 | 536 | 3.530 |
Why?
|
Visual Fields | 28 | 2024 | 1054 | 3.310 |
Why?
|
Intraocular Pressure | 31 | 2024 | 1288 | 3.160 |
Why?
|
Tomography, Optical Coherence | 19 | 2024 | 2877 | 2.250 |
Why?
|
Optic Nerve Diseases | 6 | 2024 | 342 | 1.810 |
Why?
|
Visual Field Tests | 18 | 2024 | 411 | 1.580 |
Why?
|
Glaucoma, Angle-Closure | 5 | 2023 | 191 | 1.540 |
Why?
|
Nerve Fibers | 9 | 2024 | 708 | 1.450 |
Why?
|
Cornea | 10 | 2023 | 1326 | 1.440 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 2 | 2022 | 111 | 1.420 |
Why?
|
Retinal Ganglion Cells | 11 | 2024 | 806 | 1.400 |
Why?
|
Prostheses and Implants | 11 | 2023 | 1270 | 1.330 |
Why?
|
Fluorescein Angiography | 3 | 2024 | 1044 | 1.200 |
Why?
|
Artificial Organs | 6 | 2019 | 149 | 1.180 |
Why?
|
Vision Disorders | 10 | 2024 | 1084 | 1.050 |
Why?
|
Retinal Vessels | 6 | 2024 | 836 | 1.020 |
Why?
|
Glaucoma Drainage Implants | 4 | 2019 | 106 | 0.890 |
Why?
|
Bruch Membrane | 3 | 2019 | 65 | 0.890 |
Why?
|
Visual Acuity | 13 | 2022 | 2642 | 0.860 |
Why?
|
Trabeculectomy | 2 | 2022 | 174 | 0.840 |
Why?
|
Gonioscopy | 2 | 2020 | 155 | 0.720 |
Why?
|
Filtering Surgery | 2 | 2015 | 33 | 0.620 |
Why?
|
Laser Therapy | 2 | 2022 | 1089 | 0.610 |
Why?
|
Fluocinolone Acetonide | 1 | 2017 | 38 | 0.590 |
Why?
|
Uveitis, Anterior | 1 | 2017 | 102 | 0.560 |
Why?
|
Tonometry, Ocular | 8 | 2022 | 235 | 0.560 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 250 | 0.560 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 346 | 0.550 |
Why?
|
Coated Materials, Biocompatible | 1 | 2017 | 312 | 0.500 |
Why?
|
Moraxellaceae Infections | 1 | 2015 | 7 | 0.500 |
Why?
|
Phacoemulsification | 3 | 2023 | 149 | 0.480 |
Why?
|
Cross-Sectional Studies | 19 | 2024 | 25956 | 0.450 |
Why?
|
Keratoplasty, Penetrating | 3 | 2022 | 144 | 0.430 |
Why?
|
Retina | 4 | 2023 | 2635 | 0.430 |
Why?
|
Eye Abnormalities | 1 | 2015 | 241 | 0.410 |
Why?
|
Imaging, Three-Dimensional | 3 | 2024 | 4048 | 0.400 |
Why?
|
Endophthalmitis | 1 | 2015 | 257 | 0.400 |
Why?
|
Microvessels | 3 | 2021 | 572 | 0.390 |
Why?
|
Eye Infections, Bacterial | 1 | 2015 | 239 | 0.390 |
Why?
|
Retinoscopy | 1 | 2011 | 26 | 0.390 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2019 | 4342 | 0.380 |
Why?
|
Scotoma | 3 | 2022 | 130 | 0.360 |
Why?
|
Retinal Detachment | 1 | 2015 | 427 | 0.350 |
Why?
|
Macula Lutea | 1 | 2011 | 169 | 0.340 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2244 | 0.330 |
Why?
|
Ophthalmology | 1 | 2015 | 549 | 0.320 |
Why?
|
Retinal Hemorrhage | 2 | 2020 | 95 | 0.310 |
Why?
|
Artificial Intelligence | 5 | 2020 | 2551 | 0.310 |
Why?
|
Retrospective Studies | 28 | 2023 | 80168 | 0.310 |
Why?
|
Capillaries | 3 | 2021 | 744 | 0.290 |
Why?
|
Thiazolidinediones | 2 | 2008 | 460 | 0.290 |
Why?
|
Humans | 68 | 2024 | 758406 | 0.270 |
Why?
|
Aged | 34 | 2024 | 168218 | 0.260 |
Why?
|
Nails | 2 | 2018 | 295 | 0.250 |
Why?
|
PPAR gamma | 1 | 2008 | 482 | 0.250 |
Why?
|
Regional Blood Flow | 2 | 2019 | 1486 | 0.250 |
Why?
|
Exfoliation Syndrome | 2 | 2017 | 113 | 0.240 |
Why?
|
Fundus Oculi | 2 | 2024 | 540 | 0.240 |
Why?
|
Prosthesis Implantation | 5 | 2022 | 590 | 0.230 |
Why?
|
Ocular Hypotension | 1 | 2023 | 23 | 0.220 |
Why?
|
Microcirculation | 2 | 2019 | 1273 | 0.220 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2359 | 0.210 |
Why?
|
Densitometry | 2 | 2020 | 151 | 0.210 |
Why?
|
Middle Aged | 32 | 2024 | 219568 | 0.210 |
Why?
|
Curriculum | 1 | 2015 | 3717 | 0.200 |
Why?
|
Prosthesis Design | 2 | 2020 | 2105 | 0.200 |
Why?
|
Angiogenesis Inhibitors | 3 | 2008 | 2047 | 0.180 |
Why?
|
Burns, Chemical | 2 | 2019 | 122 | 0.180 |
Why?
|
Ocular Hypertension | 2 | 2020 | 206 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2024 | 3339 | 0.180 |
Why?
|
Endothelium, Corneal | 1 | 2022 | 214 | 0.170 |
Why?
|
Female | 34 | 2024 | 390323 | 0.170 |
Why?
|
Case-Control Studies | 5 | 2023 | 22029 | 0.170 |
Why?
|
Refractive Surgical Procedures | 1 | 2019 | 22 | 0.170 |
Why?
|
Clinical Competence | 1 | 2015 | 4775 | 0.170 |
Why?
|
Bayes Theorem | 3 | 2022 | 2322 | 0.170 |
Why?
|
Aniridia | 1 | 2019 | 36 | 0.170 |
Why?
|
Male | 31 | 2024 | 358747 | 0.170 |
Why?
|
Postoperative Complications | 4 | 2019 | 15637 | 0.170 |
Why?
|
Disease Progression | 8 | 2024 | 13468 | 0.160 |
Why?
|
Follow-Up Studies | 8 | 2022 | 39059 | 0.160 |
Why?
|
Diabetic Retinopathy | 1 | 2008 | 1267 | 0.160 |
Why?
|
Artifacts | 2 | 2023 | 1897 | 0.150 |
Why?
|
Blood Sedimentation | 1 | 2019 | 234 | 0.150 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 256 | 0.150 |
Why?
|
Cataract Extraction | 2 | 2019 | 465 | 0.150 |
Why?
|
Retinal Artery | 1 | 2018 | 109 | 0.140 |
Why?
|
Angiography | 1 | 2022 | 1599 | 0.140 |
Why?
|
Anterior Eye Segment | 1 | 2017 | 141 | 0.140 |
Why?
|
Anti-Bacterial Agents | 1 | 2015 | 7403 | 0.130 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58683 | 0.130 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3069 | 0.130 |
Why?
|
Internship and Residency | 1 | 2015 | 5865 | 0.120 |
Why?
|
Prosthesis Failure | 1 | 2020 | 1198 | 0.120 |
Why?
|
Blister | 1 | 2015 | 86 | 0.120 |
Why?
|
Prospective Studies | 5 | 2020 | 54137 | 0.120 |
Why?
|
Algorithms | 4 | 2021 | 13961 | 0.110 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 706 | 0.110 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2016 | 244 | 0.110 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1780 | 0.100 |
Why?
|
Retinal Diseases | 1 | 2018 | 702 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 3801 | 0.100 |
Why?
|
Blindness | 1 | 2015 | 582 | 0.090 |
Why?
|
Leptin | 1 | 2019 | 1591 | 0.090 |
Why?
|
Antihypertensive Agents | 1 | 2020 | 2016 | 0.090 |
Why?
|
Diabetes Mellitus | 1 | 2008 | 5816 | 0.080 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1076 | 0.080 |
Why?
|
Ciliary Body | 2 | 2021 | 166 | 0.080 |
Why?
|
Regression Analysis | 2 | 2016 | 6354 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20055 | 0.080 |
Why?
|
Models, Statistical | 2 | 2016 | 5070 | 0.080 |
Why?
|
Endoscopy | 1 | 2019 | 1834 | 0.080 |
Why?
|
Adult | 16 | 2024 | 219935 | 0.080 |
Why?
|
Educational Measurement | 1 | 2015 | 1248 | 0.080 |
Why?
|
Microscopic Angioscopy | 2 | 2018 | 20 | 0.080 |
Why?
|
Coffee | 1 | 2012 | 582 | 0.070 |
Why?
|
Teaching | 1 | 2015 | 1168 | 0.070 |
Why?
|
Caffeine | 1 | 2012 | 701 | 0.070 |
Why?
|
Recovery of Function | 1 | 2017 | 2970 | 0.070 |
Why?
|
Antirheumatic Agents | 1 | 2016 | 1368 | 0.070 |
Why?
|
Thiazoles | 2 | 2003 | 1510 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15651 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 21272 | 0.060 |
Why?
|
Macular Edema | 1 | 2008 | 374 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2023 | 64378 | 0.060 |
Why?
|
Central Nervous System Stimulants | 1 | 2012 | 1176 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14490 | 0.050 |
Why?
|
Medical Records | 1 | 2008 | 1406 | 0.050 |
Why?
|
Chronic Disease | 1 | 2017 | 9267 | 0.050 |
Why?
|
Preoperative Period | 2 | 2014 | 553 | 0.050 |
Why?
|
Risk Reduction Behavior | 1 | 2008 | 1098 | 0.050 |
Why?
|
Isoantigens | 1 | 2004 | 552 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14641 | 0.050 |
Why?
|
Diabetes Complications | 1 | 2008 | 1317 | 0.050 |
Why?
|
Blood Pressure | 2 | 2018 | 8451 | 0.050 |
Why?
|
Laser Coagulation | 1 | 2023 | 329 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8650 | 0.050 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2003 | 411 | 0.050 |
Why?
|
Young Adult | 5 | 2020 | 58808 | 0.050 |
Why?
|
Heart Rate | 1 | 2012 | 4166 | 0.040 |
Why?
|
Image Enhancement | 1 | 2011 | 2880 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2014 | 4412 | 0.040 |
Why?
|
Risk Factors | 3 | 2022 | 73809 | 0.040 |
Why?
|
Eye Burns | 1 | 2019 | 65 | 0.040 |
Why?
|
False Negative Reactions | 1 | 2020 | 573 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9460 | 0.040 |
Why?
|
Oligopeptides | 1 | 2004 | 1185 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 855 | 0.040 |
Why?
|
Computer Simulation | 1 | 2011 | 6201 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2018 | 91 | 0.040 |
Why?
|
Polymethyl Methacrylate | 1 | 2017 | 131 | 0.030 |
Why?
|
Microscopy, Video | 1 | 2017 | 242 | 0.030 |
Why?
|
Retinal Vein Occlusion | 1 | 2018 | 149 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2019 | 956 | 0.030 |
Why?
|
Language | 1 | 2024 | 1532 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2004 | 2532 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2003 | 1090 | 0.030 |
Why?
|
Retinal Neurons | 1 | 2015 | 66 | 0.030 |
Why?
|
Titanium | 1 | 2017 | 484 | 0.030 |
Why?
|
Aneurysm | 1 | 2018 | 336 | 0.030 |
Why?
|
Acid-Base Equilibrium | 1 | 2014 | 180 | 0.030 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2008 | 3432 | 0.030 |
Why?
|
Rabbits | 1 | 2019 | 4772 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15225 | 0.030 |
Why?
|
Leisure Activities | 1 | 2014 | 306 | 0.030 |
Why?
|
Sunlight | 1 | 2014 | 337 | 0.030 |
Why?
|
Israel | 1 | 2014 | 721 | 0.030 |
Why?
|
Occupations | 1 | 2014 | 515 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2002 | 4901 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2210 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 955 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15785 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2003 | 13591 | 0.020 |
Why?
|
Potassium | 1 | 2014 | 1310 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3563 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5862 | 0.020 |
Why?
|
Postoperative Care | 1 | 2016 | 1471 | 0.020 |
Why?
|
Postoperative Period | 1 | 2014 | 1812 | 0.020 |
Why?
|
Databases, Factual | 1 | 2024 | 7980 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2018 | 1793 | 0.020 |
Why?
|
Cataract | 1 | 2014 | 827 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8530 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 819 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2012 | 2048 | 0.020 |
Why?
|
Adolescent | 3 | 2020 | 87892 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2014 | 2058 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2008 | 12075 | 0.010 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2004 | 321 | 0.010 |
Why?
|
H-2 Antigens | 1 | 2004 | 358 | 0.010 |
Why?
|
Quantum Theory | 1 | 2003 | 68 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7338 | 0.010 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2003 | 114 | 0.010 |
Why?
|
Transcription Factors | 1 | 2002 | 12094 | 0.010 |
Why?
|
Hydrogen | 1 | 2003 | 171 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2014 | 4540 | 0.010 |
Why?
|
Molecular Conformation | 1 | 2003 | 543 | 0.010 |
Why?
|
Thermodynamics | 1 | 2003 | 595 | 0.010 |
Why?
|
Alanine | 1 | 2004 | 603 | 0.010 |
Why?
|
Protein Binding | 2 | 2004 | 9311 | 0.010 |
Why?
|
Clone Cells | 1 | 2004 | 1660 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 590 | 0.010 |
Why?
|
Arginine | 1 | 2004 | 933 | 0.010 |
Why?
|
Serine | 1 | 2004 | 828 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2004 | 1734 | 0.010 |
Why?
|
Lysine | 1 | 2004 | 998 | 0.010 |
Why?
|
Crystallography, X-Ray | 1 | 2004 | 1974 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2004 | 3069 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12262 | 0.010 |
Why?
|
Animals | 4 | 2019 | 167768 | 0.010 |
Why?
|
Mice | 2 | 2019 | 81101 | 0.010 |
Why?
|
Cattle | 1 | 2002 | 3845 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 29557 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41256 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 39872 | 0.010 |
Why?
|
Ligands | 1 | 2002 | 3258 | 0.010 |
Why?
|
Neoplasms | 1 | 2003 | 22032 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2002 | 3617 | 0.010 |
Why?
|
Binding Sites | 1 | 2003 | 6036 | 0.010 |
Why?
|
Models, Molecular | 1 | 2003 | 5410 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2004 | 13447 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2004 | 9518 | 0.010 |
Why?
|
Cell Line | 1 | 2004 | 15591 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2003 | 7985 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 16886 | 0.000 |
Why?
|
United States | 1 | 2014 | 72136 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 2004 | 22003 | 0.000 |
Why?
|
Concepts
(229)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(49)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_